Table 2.

Summary of clinical outcomes

	From HSCT	From first VAX*
Follow-up time among survivors
Median (range), mo	67 (60-81)
5-y OS (95% CI)	39% (23-55)	39% (23, 55)
5-y PFS (95% CI)	39% (23-55)	39% (23-55)
2-y cumulative incidence of relapse (95% CI)	48% (30-64)
2-y cumulative incidence of NRM (95% CI)	9% (2.2-22)
180-d cumulative incidence of grade 2-4 aGVHD (95% CI)	24% (11-40)
2-y cumulative incidence of cGVHD relapse (95% CI)	33% (17-50)

VAX, vaccination.

^*Median time from HSCT day 0 to VAX 1 = 35 d.